Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients

• Main Authors: Atsuko Ashida, Kaori Sakaizawa, Hisashi Uhara, Ryuhei Okuyama
• Format: Article
• Language: English
• Published: Society for Publication of Acta Dermato-Venereologica 2017-08-01
• Series: Acta Dermato-Venereologica
• Subjects: melanoma; circulatingtumourDNA; anti-programmedcelldeath-1antibody; BRAF; NRAS; dropletdigitalPCR
• Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2748

Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAFmutant or NRASmutant) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2–4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy.